ReviewHuman vaccines & immunotherapeutics2013
Current status of immunotherapy for the treatment of biliary tract cancer.
Review in Human vaccines & immunotherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Advancing biliary tract malignancy treatment: emerging frontiers in cell-based therapies.Frontiers in immunology · 2025Review
- Human Vγ9Vδ2 T cell expansion and their cytotoxic responses against cholangiocarcinoma.Scientific reports · 2024Article
- Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma.Frontiers in oncology · 2023Review
- Clinicopathological characteristics and prognostic factors for intrahepatic cholangiocarcinoma: a population-based study.Scientific reports · 2021Article
- Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer.Journal of pathology and translational medicine · 2020Article
- Targeted therapy in biliary tract cancers-current limitations and potentials in the future.Journal of gastrointestinal oncology · 2017Review
- Opisthorchiasis and cholangiocarcinoma in Southeast Asia: an unresolved problem.International journal of general medicine · 2017Review
- Activation or suppression of the immune response mediators in biliary tract cancer (BTC) patients: a systematic review and meta-analysis.Journal of Cancer · 2017Article
- The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.Oncotarget · 2016Review
- Molecular genetics and targeted therapeutics in biliary tract carcinoma.World journal of gastroenterology · 2016Review
- Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies.World journal of gastrointestinal oncology · 2015Review
- Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future.Current problems in cancerReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biliary tract cancer (BTC) is one of the most aggressive malignancies. Although various promising regimens of chemotherapeutic and/or molecular targeted agents have been developed, further treatment modalities, including immunotherapies, still remain to be established for refractory patients who are unresponsive to or relapse after currently available therapeutic options for BTC. Recently, several clinical trials of immunotherapies, including peptide-based vaccines and dendritic cell (DC)-based vaccines, have been reported with promising results. Here we summarize the data from phase I or phase II clinical trials of immunotherapies for BTC. In particular, we introduce our novel immunotherapeutic approach called personalized peptide vaccine (PPV), in which HLA-matched peptides were selected and administered based on the pre-existing host immunity before vaccination, for the treatment of advanced BTC. Further clinical trials would be recommended to prove clinical benefits of these novel immunotherapeutic approaches. Recently concomitant treatments, such as chemotherapies and immune checkpoint blockade, have been reported to enhance the therapeutic effects of cancer immunotherapies through multiple coordinated immune mechanisms. Additional therapies in combination with immunotherapies could produce synergistic effects in the treatment of advanced BTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.